N4P — N4 Pharma Income Statement
0.000.00%
Last trade - 00:00- £4.99m
- £3.27m
- £0.01m
Annual income statement for N4 Pharma, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0.002 | 0.007 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1.56 | 1.84 | 1.19 | 1.43 | 1.23 |
| Operating Profit | -1.56 | -1.84 | -1.19 | -1.42 | -1.22 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -1.57 | -1.84 | -1.19 | -1.42 | -1.22 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.3 | -1.54 | -1.03 | -1.28 | -1.12 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.3 | -1.54 | -1.03 | -1.27 | -1.06 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.3 | -1.54 | -1.03 | -1.27 | -1.06 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.01 | -0.009 | -0.006 | -0.005 | -0.003 |